High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia.
Fiche publication
Date publication
juin 2024
Journal
Blood
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DELMER Alain
Tous les auteurs :
Durot E, Roos-Weil D, Chauchet A, Decroocq J, Di Blasi R, Gastinne T, Bensaber H, Cheminant M, Jacquet C, Guidez S, Gros FX, Bachy E, Coste A, Cony-Makhoul P, Treon SP, Delmer A, Reshef R, Le Gouill S, Castillo JJ, Houot R
Lien Pubmed
Résumé
Histologic transformation of Waldenström macroglobulinemia (HT-WM) carries a poor prognosis with standard treatments. Here, we report the first series of HT-WM treated with chimeric antigen receptor T cells showing a high efficacy and no unexpected toxicity.
Mots clés
Humans, Waldenstrom Macroglobulinemia, therapy, Male, Aged, Immunotherapy, Adoptive, methods, Female, Antigens, CD19, immunology, Middle Aged, Receptors, Chimeric Antigen, immunology, T-Lymphocytes, immunology, Treatment Outcome
Référence
Blood. 2024 06 27;143(26):2804-2807